Indivumed Launches Fluorescent Multiplex IHC

Toward meeting your research needs, Indivumed is pleased to announce we have complemented our high-quality immunohistochemistry (IHC) services by offering Fluorescent Multiplex IHC with Tyramide Signal Amplification. With this service, up to six targets of interest can be analyzed on one tissue section. Tyramide Signal Amplification ensures the highest sensitivity in fully automated multiplex staining, and whole-slide scans, including seven fluorescent layers, allow complex digital image analyses and long-term storage.

Request a quote

Indivumed will have a booth at the T5 JobMesse (job fair) on 11 October, 2017, in Hamburg.

Please join us to explore the benefits of a career with Indivumed. 


September 19, 2017

Indivumed and Helomics partner to unlock the power of cancer biospecimens for drug discovery and development

Indivumed GmbH (Indivumed) and Helomics® Corporation (Helomics) announce their intentions to collaborate to analyze human cancer biospecimens and annotated clinical data from consenting patients around the world, enabling cutting-edge basic and translational research in cancer.

Read More

August 02, 2017

MedStar Health Collaborates with Indivumed to Advance Precision Oncology Research

MedStar Health will collaborate with Indivumed to advance our understanding of the molecular basis of cancer through collection and analysis of biospecimens and clinical data, making possible new individualized diagnosis and treatment of cancer.

Read More

June 01, 2017

Indivumed and Intermed to form strategic alliance

Intermed invests in Indivumed in order to accelerate the expansion of Indivumed’s worldwide leading Cancer Database.

Read More

April 11, 2017

Mayor Olaf Scholz honors Hamburg as international medical research location

Hamburg's First Mayor, Olaf Scholz, and international guests from science and business honored Indivumed at its 15-year anniversary.

Read More